# Canakinumab for Pyoderma Gangrenosum

> **NCT01302795** · PHASE2 · COMPLETED · sponsor: **University of Zurich** · enrollment: 5 (actual)

## Conditions studied

- Pyoderma Gangrenosum

## Interventions

- **DRUG:** Canakinumab

## Key facts

- **NCT ID:** NCT01302795
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2014-08
- **Final completion:** 2015-11
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2016-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01302795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01302795, "Canakinumab for Pyoderma Gangrenosum". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01302795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*